☆ 4.7 Letter

In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactam

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Journal

CLINICAL MICROBIOLOGY AND INFECTION

Volume 28, Issue 5, Pages 749-751

Publisher

ELSEVIER SCI LTD

DOI: 10.1016/j.cmi.2022.01.025

Keywords

-

Categories

Infectious Diseases Microbiology

Funding

Italian Ministry of Health [GR-2018-12367572]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Infectious Diseases

Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates

Sofia Maraki, Viktoria Eirini Mavromanolaki, Eleni Magkafouraki, Panagiotis Moraitis, Dimitra Stafylaki, Anna Kasimati, Effie Scoulica

Summary: KPC remains the predominant carbapenemase among K. pneumoniae, followed by NDM. Novel agents such as plazomicin show promise in combating infections by carbapenemase-producing K. pneumoniae. Continuous surveillance and enhanced antimicrobial stewardship are necessary due to the emergence of resistance to these agents.

INFECTION (2022)

Add to Collection

Article Infectious Diseases

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland

Patrice Nordmann, Maxime Bouvier, Laurent Poirel

Summary: Carbapenemase-producing Enterobacterales (CPE) are a major health concern globally, with limited therapeutic options in Switzerland. This study evaluated the susceptibility of CPE isolates recovered in Switzerland from 2018 to 2020 to novel β-lactam/β-lactamase inhibitor combinations, including ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam. The majority of clinical CPE isolates were Klebsiella pneumoniae and Escherichia coli, and the distribution of carbapenemases varied. The study found that meropenem-vaborbactam had the highest susceptibility among the three combinations, followed by ceftazidime-avibactam and imipenem-relebactam. These findings can help optimize first-line therapy for CPE infections.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2023)

Add to Collection

Article Infectious Diseases

Susceptibility of OXA-48-producing Enterobacterales to imipenem/relebactam, meropenem/vaborbactam and ceftazidime/avibactam

Remy A. Bonnin, Sandrine Bernabeu, Cecile Emeraud, Elodie Creton, Oceane Vanparis, Thierry Naas, Agnes B. Jousset, Laurent Dortet

Summary: This study demonstrates that the addition of relebactam and vaborbactam did not significantly modify the susceptibility of OXA-48-like-producing Enterobacterales to imipenem and meropenem. However, the addition of avibactam strongly restored ceftazidime susceptibility.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)

Add to Collection

Article Infectious Diseases

Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-β-lactamase-producing Klebsiella pneumoniae

Sofia Maraki, Viktoria Eirini Mavromanolaki, Panagiotis Moraitis, Dimitra Stafylaki, Anna Kasimati, Eleni Magkafouraki, Effie Scoulica

Summary: The study evaluated the in vitro efficacy of different antibiotic combinations against multidrug-resistant Klebsiella pneumoniae, showing that certain combinations exhibited synergy. Further clinical studies are needed to confirm the efficacy of these antimicrobial combinations.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)

Add to Collection

Article Microbiology

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam

Naphat Satapoomin, Punyawee Dulyayangkul, Matthew B. Avison

Summary: The study reveals a variant of Klebsiella pneumoniae that exhibits resistance to multiple antibiotics, including ceftazidime-avibactam and meropenem-vaborbactam. Further mutations and enzyme production are required for resistance to other antibiotics.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Immunology

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Klebsiella pneumoniae-Producing KPC-31, a D179Y Variant of KPC-3

Giusy Tiseo, Marco Falcone, Alessandro Leonildi, Cesira Giordano, Simona Barnini, Gabriele Arcari, Alessandra Carattoli, Francesco Menichetti

Summary: A 68-year-old man had recurrent bacteremia caused by a K. pneumoniae strain producing the KPC-3 variant enzyme, resistant to ceftazidime-avibactam but susceptible to meropenem after treatment.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Article Microbiology

In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae

Jacqueline Findlay, Celine Rens, Laurent Poirel, Patrice Nordmann

Summary: Carbapenem-resistant Enterobacterales, such as KPC-producing Klebsiella pneumoniae, pose a major threat to public health. A study evaluated the mutations that lead to imipenem-relebactam (IPM-REL) resistance in 5 KPC-producing K. pneumoniae strains. Mutations were found in OmpK36 and KPC, resulting in decreased susceptibility to beta-lactams. The study also highlighted the importance of OmpK36 in IPM-REL resistance.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Ceftazidime-Avibactam in Combination with Imipenem as Salvage Therapy for ST11 KPC-33-Producing Klebsiella pneumoniae

Li Ding, Siquan Shen, Renru Han, Dandan Yin, Yan Guo, Fupin Hu

Summary: This case provides a reference for treating infections caused by K. pneumoniae with a KPC variant in countries lacking new antimicrobial agents.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Infectious Diseases

Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study

Laura Campogiani, Pietro Vitale, Alessandra Lodi, Alessandra Imeneo, Carla Fontana, Cartesio D'Agostini, Mirko Compagno, Luigi Coppola, Ilaria Spalliera, Vincenzo Malagnino, Elisabetta Teti, Marco Iannetta, Massimo Andreoni, Loredana Sarmati

Summary: This study aimed to collect and describe real-life data on CAZ-AVI-resistant Klebsiella pneumoniae isolates in a University Hospital. The results showed that prior use of CAZ-AVI was associated with the emergence of drug resistance.

ANTIBIOTICS-BASEL (2023)

Add to Collection

Article Microbiology

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman

Summary: Ceftazidime/avibactam is an important treatment option for infections caused by KPC-Kp, but resistance can emerge during treatment. The study aimed to define the concentrations required to suppress regrowth in ceftazidime/avibactam susceptible isolates and identify active therapies against ceftazidime/avibactam-resistant KPC-Kp.

FRONTIERS IN MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient

Paolo Gaibani, Linda Bussini, Stefano Amadesi, Michele Bartoletti, Federica Bovo, Tiziana Lazzarotto, Pierluigi Viale, Simone Ambretti

Summary: This study described the emergence of cross-resistance to MER-VAB and IMI-REL in a KPC-Kp strain isolated from a hematological patient, highlighting the potential development and diffusion of new multidrug resistance traits.

MICROORGANISMS (2022)

Add to Collection

Article Infectious Diseases

Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam

Vincenzo Di Pilato, Luigi Principe, Lilia Andriani, Noemi Aiezza, Marco Coppi, Silvia Ricci, Tommaso Giani, Francesco Luzzaro, Gian Maria Rossolini

Summary: This article reports an outbreak caused by carbapenemase-producing Klebsiella pneumoniae that is resistant to ceftazidime/avibactam and variably resistant to carbapenem-based beta-lactam/beta-lactamase inhibitor combinations. The overproduction of KPC-3 was identified as the main mechanism of cross-resistance to ceftazidime/avibactam and meropenem/vaborbactam, while resistance to imipenem/relebactam was less affected.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Add to Collection

Article Infectious Diseases

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae : Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations

A. Oliva, D. Al Ismail, G. Arcari, MC. Miele, E. Casali, F. Sacco, L. Volpicelli, M. De Angelis, M. T. Mascellino, F. Cancelli, G. Raponi, A. Carattoli, M. Venditti

Summary: This study describes the clinical characteristics of patients infected with Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) and explores the in vitro activity of fosfomycin-containing combinations. The results show that the combination of fosfomycin and meropenem exhibits synergistic activity in 40% of cases, suggesting it as a valuable therapeutic option for KPC variants.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2023)

Add to Collection

Article Infectious Diseases

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020

Federica Bovo, Donatella Lombardo, Tiziana Lazzarotto, Simone Ambretti, Paolo Gaibani

Summary: This study assessed the resistance to novel beta-lactamase inhibitor combinations in KPC-producing K. pneumoniae strains isolated from patients with bloodstream infections. The results showed varying resistance rates to different beta-lactamase inhibitor combinations, with IMI-REL being the most effective. Genotypic analysis revealed mutations in the bla(KPC-3) gene in KPC-Kp strains resistant to CAZ-AVI, while strains resistant to CAZ-AVI, MER-VAB, and/or IMI-REL all carried the bla(KPC-3) gene.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Infectious Diseases

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections

Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes

Summary: This study evaluated the in vitro activity of four new generation beta-lactam/beta-lactamase inhibitor combinations against P. aeruginosa isolates from patients with skin and soft tissue infections worldwide. The results demonstrated potent activity and broad coverage of these recently approved drugs against contemporary P. aeruginosa isolates.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Rectal screening for carbapenemase-producing Enterobacteriaceae: a proposed workflow

Claudio Foschi, Paolo Gaibani, Donatella Lombardo, Maria Carla Re, Simone Ambretti

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)

Add to Collection

Letter Infectious Diseases

Evaluation of five carbapenemase detection assays for Enterobacteriaceae harbouring bla(KPC) variants associated with ceftazidime/avibactam resistance

Paolo Gaibani, Donatella Lombardo, Claudio Foschi, Maria Carla Re, Simone Ambretti

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Letter Public, Environmental & Occupational Health

Carbapenemase-producing Enterobacterales: changing epidemiology in a highly endemic Italian area

C. Foschi, D. Lombardo, P. Gaibani, M. C. Re, S. Ambretti

JOURNAL OF HOSPITAL INFECTION (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: A multicenter before-and-after cross-sectional study

Renato Pascale, Linda Bussini, Paolo Gaibani, Federica Bovo, Giacomo Fornaro, Donatella Lombardo, Simone Ambretti, Giulia Pensalfine, Lucia Appolloni, Michele Bartoletti, Sara Tedeschi, Fabio Tumietto, Russell Lewis, Pierluigi Viale, Maddalena Giannella

Summary: This study assessed the incidence of colonization and infection with CPE and CR-Ab in ICUs before and during the COVID-19 pandemic. The results showed no significant change in CPE colonization and infection, but a significant increase in CR-Ab colonization and infection. The CR-Ab strains belonged to the same clonal lineage and horizontal transmission was observed. Therefore, infection control activities should be conducted during the pandemic and adjusted according to the situation.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

The lower respiratory tract microbiome of critically ill patients with COVID-19

Paolo Gaibani, Elisa Viciani, Michele Bartoletti, Russell E. Lewis, Tommaso Tonetti, Donatella Lombardo, Andrea Castagnetti, Federica Bovo, Clara Solera Horna, Marco Ranieri, Pierluigi Viale, Maria Carla Re, Simone Ambretti

Summary: COVID-19 critically ill patients have a different lung microbiome compared to non-COVID-19 patients, potentially leading to bacterial superinfection. Infection rates, especially with multidrug resistant pathogens, may increase due to SARS-CoV-2 infection and antibiotic pressure.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Infectious Diseases

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018

Paolo Gaibani, Donatella Lombardo, Linda Bussini, Federica Bovo, Beatrice Munari, Maddalena Giannella, Michele Bartoletti, Pierluigi Viale, Tiziana Lazzarotto, Simone Ambretti

Summary: In a large Italian hospital, the incidence of meropenem/vaborbactam-resistance among KPC-producing K. pneumoniae bloodstream infection was evaluated, with 8% of KPC-Kp exhibiting resistance. Resistance was associated with porins mutations and reduced susceptibility to ceftazidime/avibactam and carbapenems, but no specific mutation was linked to cross-resistance. Treatment outcomes were not influenced by specific antimicrobial treatments or cross-resistance.

ANTIBIOTICS-BASEL (2021)

Add to Collection

Article Immunology

The Gut Microbiota of Critically Ill Patients With COVID-19

Paolo Gaibani, Federica D'Amico, Michele Bartoletti, Donatella Lombardo, Simone Rampelli, Giacomo Fornaro, Simona Coladonato, Antonio Siniscalchi, Maria Carla Re, Pierluigi Viale, Patrizia Brigidi, Silvia Turroni, Maddalena Giannella

Summary: The gut microbiota (GM) of COVID-19 patients showed severe dysbiosis, reduced diversity, loss of health-associated microorganisms, and enrichment of potential pathogens, particularly Enterococcus.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

Application of Fourier transform infrared spectroscopy spectroscopy for real-time typing of Acinetobacter baumannii outbreak in intensive care unit

Donatella Lombardo, Miriam Cordovana, Francesca Deidda, Marco Pane, Simone Ambretti

Summary: The study investigated the use of IR Biotyper (IRBT) to track and monitor the spread of multidrug-resistant A. baumannii outbreak. The results showed that IR Biotyper is a promising tool for real-time hospital hygiene, enabling prompt and reliable typing.

FUTURE MICROBIOLOGY (2021)

Add to Collection

Article Infectious Diseases

Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient

Paolo Gaibani, Milo Gatti, Matteo Rinaldi, Cristina Crovara Pesce, Tiziana Lazzarotto, Maddalena Giannella, Donatella Lombardo, Stefano Amadesi, Pierluigi Viale, Federico Pea, Simone Ambretti

Summary: The study described the dynamic evolution of a KPC-Kp infection in a critically ill patient treated with CAZ-AVI combination therapy. Results indicated high adaptability of KPC to CAZ-AVI, with resistance evolution during treatment, emphasizing the importance of identifying optimal PK/PD targets to prevent recurrence.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Microbiology

Virulence Determinants in Staphylococcus aureus Clones Causing Osteomyelitis in Italy

Fernanda Pimentel de Araujo, Mattia Pirolo, Monica Monaco, Maria Del Grosso, Simone Ambretti, Donatella Lombardo, Tiziana Cassetti, Raffaele Gargiulo, Eleonora Riccobono, Paolo Visca, Annalisa Pantosti

Summary: The study in Italy on osteomyelitis caused by Staphylococcus aureus found a diverse distribution of clonal complexes, with a high proportion of methicillin-resistant strains. The most common lineages were CC22, CC5, CC8, CC30, and CC15, with variations in virulence genes among different complexes.

FRONTIERS IN MICROBIOLOGY (2022)

Add to Collection

Review Infectious Diseases

Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing

Paolo Gaibani, Tommaso Giani, Federica Bovo, Donatella Lombardo, Stefano Amadesi, Tiziana Lazzarotto, Marco Coppi, Gian Maria Rossolini, Simone Ambretti

Summary: Multidrug resistance (MDR) is a serious global threat due to the rapid spread of MDR pathogens and limited treatment options. New beta-lactams/beta-lactamase inhibitor combinations (beta L-beta LICs) have shown promise for treating MDR Gram-negative infections. However, resistance to these novel molecules has started to emerge. This review summarizes the mechanisms of resistance to ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam in MDR Gram-negative microorganisms, with a focus on antimicrobial activities and resistance traits related to novel beta L-PLICs. The detection methods for antimicrobial susceptibility testing of these molecules are also discussed.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Infectious Diseases

Multicentre Evaluation of the EUCAST Rapid Antimicrobial Susceptibility Testing (RAST) Extending Analysis to 16-20 Hours Reading Time

Gabriele Bianco, Donatella Lombardo, Guido Ricciardelli, Matteo Boattini, Sara Comini, Rossana Cavallo, Cristina Costa, Simone Ambretti

Summary: The study evaluated the reliability and performance of the EUCAST RAST method, and found that it accurately determined microbial susceptibility to main antimicrobials. The method showed potential for antimicrobial de-escalation interventions.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Infectious Diseases

Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against KPC-Producing K. pneumoniae Collected from Bacteremic Patients, 2018 to 2020

Federica Bovo, Donatella Lombardo, Tiziana Lazzarotto, Simone Ambretti, Paolo Gaibani

Summary: This study assessed the resistance to novel beta-lactamase inhibitor combinations in KPC-producing K. pneumoniae strains isolated from patients with bloodstream infections. The results showed varying resistance rates to different beta-lactamase inhibitor combinations, with IMI-REL being the most effective. Genotypic analysis revealed mutations in the bla(KPC-3) gene in KPC-Kp strains resistant to CAZ-AVI, while strains resistant to CAZ-AVI, MER-VAB, and/or IMI-REL all carried the bla(KPC-3) gene.

ANTIBIOTICS-BASEL (2022)

Add to Collection

Article Microbiology

Comparison of MycoPrep and the new MYCO-TB kit: rapid and efficient digestion and decontamination of respiratory specimens for the detection of Mycobacteria

Francesco Bisognin, Giulia Lombardi, Donatella Lombardo, Maria Carla Re, Paola Dal Monte

NEW MICROBIOLOGICA (2020)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.